The authors’ findings identified LRRC15 and SPP1 as hub genes in immunological mechanisms during CAVD and OA initiation and progression, as well as potential targets for drug development. This evidence concerns the gene SPP1 and congenital bilateral aplasia of vas deferens from CFTR mutation.